Netrin-1 and Placenta Accreta

Placenta Accreta Clinical Trial

Official title:

The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04683562
• Other study ID #: PA-NT1
• Status: Completed
• Phase: N/A
• Start date: December 1, 2021
• Est. completion date: June 1, 2022

Study information

• Verified date: August 2022
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: June 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• Age between 20-40 years.

• Singleton pregnancy.

• Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion Criteria:

• Multiple pregnancy,

• Fetal anomalies,

• Preterm premature rupture of membranes, or infection

• Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes

• Patients with known bleeding disorders or on anticoagulant therapy.

Related Conditions & MeSH terms

• Placenta Accreta

Intervention

Other:
• Pregnant women at 28-32 weeks
Pregnant women at gestational age 28-32 weeks
• at delivery
women delivered at term

Locations

Country	Name	City	State
Egypt	Woman's Health Hospital	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Placental Netrin-1 level	will be measured by using enzyme-linked immunosorbent assay (ELISA) in placental homogenate	4 weeks